SCHEMBL31408250

SCHEMBL31408250

CC(=O)NCc1cc2cc(Cl)c(-c3ccc(N(C)C)nc3)cc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKAG1 P54619 3/20 0.48
▸ PRKAA1 Q13131 3/20 0.48
▸ PRKAB1 Q9Y478 3/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MAP3K11 Q16584 2/20 0.38
▸ MAPT P10636 4/20 0.37
▸ MTNR1A P48039 4/20 0.36
▸ MTNR1B P49286 4/20 0.36
▸ TDO2 P48775 1/20 0.36
▸ SYK P43405 3/20 0.36
▸ AURKB Q96GD4 3/20 0.36
▸ GRM2 Q14416 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ PRKAB2 O43741 2/20 0.34
▸ PRKAA2 P54646 2/20 0.34
▸ PRKAG3 Q9UGI9 2/20 0.34
▸ PRKAG2 Q9UGJ0 2/20 0.34
▸ MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31408238 0.87 SMN1; SMN2 (0.40) PRKAG1PRKAA1PRKAB1SMN1; SMN2MAPT
SCHEMBL31408403 0.86 SMN1; SMN2 (0.37) PRKAG1PRKAA1PRKAB1SMN1; SMN2MAPT
SCHEMBL31408611 0.85 SMN1; SMN2 (0.41) PRKAG1PRKAA1PRKAB1SMN1; SMN2MAPT
SCHEMBL31408586 0.84 SMN1; SMN2 (0.40) PRKAG1PRKAA1PRKAB1SMN1; SMN2MAPT
SCHEMBL31408351 0.84 SMN1; SMN2 (0.40) PRKAG1PRKAA1PRKAB1SMN1; SMN2MAPT
SCHEMBL31408354 0.84 PRKAG1 (0.48) PRKAG1PRKAA1PRKAB1SMN1; SMN2MTNR1A
SCHEMBL31408372 0.83 TDO2 (0.39) PRKAG1PRKAA1PRKAB1SMN1; SMN2MAPT
SCHEMBL31408506 0.83 SMN1; SMN2 (0.39) PRKAG1PRKAA1PRKAB1SMN1; SMN2MAPT
SCHEMBL31408545 0.83 PTGES (0.46) PRKAG1PRKAA1PRKAB1SMN1; SMN2MTNR1A
SCHEMBL31408452 0.81 SMN1; SMN2 (0.44) PRKAG1PRKAB1SMN1; SMN2MAPTMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049604-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
Send feedback